Skip to main content
. 2021 Oct 21;17(10):e1009704. doi: 10.1371/journal.ppat.1009704

Fig 2. Identification of SARS-CoV-2-neutralizing chAbs.

Fig 2

A. Neutralization potency was measured with a pseudotyped virus neutralization assay. Data for each chAb are shown from a representative neutralization experiment. Each assay was performed in triplicate, and all data points represent the mean. B. Neutralizing chAbs inhibiting SARS-CoV-2 infection were assessed by PRNT. ChAbs were serially diluted in PBS and used to block infection of Vero E6 cells with SARS-CoV-2. Virus without chAb served as a control. Plaques formed at each dilution were counted 4 days after virus infection. The PRNT50 value was calculated by Prism software. Each assay was performed in duplicate or triplicate and all data points are shown, along with the mean ± SD. C. BLI sensorgrams and kinetics of chAb binding to SARS-CoV-2 RBD. KD is the affinity constant calculated using a 1:1 binding model. ka, association constant; kd, dissociation constant. D. Neutralization assay of D614G mutant SARS-CoV2 pseudovirus with chimeric anti-RBD antibodies. Each assay was performed in triplicate; data points represent the mean.